How Impli is Transforming Women’s Health

Making fertility treatment safer, more accessible, and more successful with real-time hormone monitoring

186 million women suffer from infertility; only 1 million have access to treatment.

“It is estimated that approximately one in six couples experiences problems with their fertility at some point in their reproductive lives (Human Reproduction, 2002). Moreover, the number of women experiencing infertility is expected to increase in the next 20 years due to women delaying childbearing. An increase in demand for infertility treatment is anticipated as a consequence (Stephen and Chandra, 1998).”

Women undergoing in vitro fertilization (IVF) encounter various obstacles, including emotional stress due to the uncertainty of treatment outcomes, financial burdens, physical discomfort from invasive procedures and hormonal medications, and concerns about medical risks and treatment failures. 

IVF treatment requires a significant time commitment, involving frequent appointments, monitoring, and procedures over several weeks or months. The process involves multiple injections, hormonal medications, and invasive procedures such as egg retrieval, which can cause physical discomfort, side effects, and potential complications for women. These physical challenges can add to the overall stress and discomfort of undergoing treatment.

IVF treatments can also be expensive, and the cost may not be covered by insurance. The financial burden of multiple treatment cycles, medications, diagnostic tests, and associated expenses can pose a significant obstacle for many couples seeking IVF. It is possible to sink years and tens of thousands of dollars into multiple rounds of unsuccessful IVF treatments.

Impli’s Solution

“In implantables, real-time hormone monitoring and sensing with aptamer-based sensors is a very new area – there are very few research papers and very few people working on it, but it’s a $10 billion global market, so there are lots of people who are interested in solving this problem and giving would-be parents the very best chance to start a family. Instead of trying to do it via general solutions, such as apps and basal temperature, we’re delivering a much more natural and precise interface to real-time hormone data.”- Anna-Luisa Schaffgotsch, Impli CEO and founder 

Impli’s pioneering innovation – the first real-time hormone monitoring device for IVF – aims to make fertility treatment safer, more accessible, and more successful. By delivering real-time insights into the patient’s hormonal profile, the implantable technology can assist fertility specialists in selecting the best treatment and optimizing medication dosages and timing.

With the ability to identify potential issues such as Ovarian Hyperstimulation Syndrome (OHSS), Impli’s device also enables management and key interventions to prevent complications – helping doctors to make the informed decisions and personalized, predictive care that can maximize the chances of a successful pregnancy.

Impli has recently been featured in the Octopus Ventures Future of Fertility Report as a “Company to Watch” in the fertility tech space.

How Femovate Helps

Impli was awarded sponsorship through Guidea’s Femovate program for ‘23-’24.

As part of the Femovate sponsorship, designers at Guidea will work closely with the Impli team to create and validate the initial digital customer experience to accompany the medical device. 

For more information about Impli, visit and follow them on LinkedIn

For more information on Femovate visit and follow us on LinkedIn

For interviews please contact Theresa Neil

Stay in touch

The application period for Femovate 2023-24 is now closed. Follow us on LinkedIn for updates and the selected startups announcement.